Return to List

Study Summary
No. ANS02-495:.......Anus; Colorectal; Esophageal; Gastric; Lung......Xin Shelley Wang......Symptom Research
.
Study Summary Title
Study Summary
Number:		ANS02-495
Study Title:Feasibility Study of the Assessment of Symptom-Related Cytokines in Lung and GI Cancer Patients Undergoing Chemoradiation Therapy
.
Physician New Patient Referral
Name:Xin Shelley WangPatients Call:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)
Dept:Symptom ResearchReferring MD
Call:		800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)
Phone:713-745-3470
Contact us about clinical trials
.
General Information
Disease Group:Anus
Colorectal
Esophageal
Gastric
Lung		Supported By:N/A
Phase of Study:N/AReturn
Visit:		N/A
Treatment
Agents:		NoneHome Care:N/A
Treatment Loc:Only at MDACC
Estimated
Length of Stay
in Houston:		N/A This is not a treatment protocol.
Description/
Intervention:		The goal of this clinical research study is to learn about chemoradiation
therapy symptoms in patients with lung, esophageal, gastric, colorectal, and
anal cancer. Researchers will learn about these symptoms by drawing blood
samples and correlating the test results with the symptoms patients experience
from the chemoradiation treatment. The study will also test the usefulness of
a special telephone system for measuring the symptoms of patients during and
following therapy.
.
Study Objectives / Outcomes
1. 1 To determine the feasibility of a study that would describe changes of certain circulating inflammatory cytokines (Interlukin-1, 6, 8, 10, 12, and tumor necrosis factor-alpha (TNF) and symptoms related to chemoradiation therapy (pre-therapy, during therapy and up to 3 months post-therapy) among patients with lung, esophageal, gastric, colorectal and anal cancer.

1.2 To determine the feasibility of studying neurocognitive function in patients with NSCLC at presentation and during chemoradiation therapy to determine the prevalence, severity, and pattern of cognitive symptoms.
.
Study Status Information
Study Activation / Registration Date:11/12/2002
IRB Review and Approval Date:09/18/2002
Study Type:Therapeutic
Recruitment Status:Terminated
Projected Accrual:225
.
Enrollment Eligibility
If you do not meet the enrollment eligibility, there may be other treatment options for you. Please Contact the Referral Office for more information.
Inclusion Criteria:1) Patients scheduled for chemoradition therapy at MDACC.

2) Adults > 18 years of age.*

3) Diagnosis of lung, esophageal, gastric, colorectal, or anal cancer.

4) English-speaking.

5) Lives in the United States.

6) Adequate vision and hearing to use the IVR system.

7) Provides written informed consent.
Exclusion Criteria:1) Patients with a current diagnosis of psychosis or dementia.

2) Patients who are unable to complete the assessment measures or refuse to participate.
.
Links
Registration Number: NCT00502502
Study Information on Clinical Trials Registry (clinicaltrials.gov)
Other Links:
.
Results

Return to Clinical Trials at M.D. Anderson Cancer Center